CJC-1295 and Ipamorelin are two of the most widely studied growth hormone secretagogue research peptides. They activate growth hormone (GH) release through complementary pathways: CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog, while Ipamorelin is a Growth Hormone Releasing Peptide (GHRP) ghrelin mimetic. This page covers their distinct mechanisms, research applications, and why they are sometimes used in combination.
All compounds referenced are for research purposes only. Not for human use.
Quick Reference
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Mechanism class | GHRH analog | GHRP (ghrelin mimetic) |
| Receptor target | GHRH receptor (pituitary) | GHSR-1a (ghrelin receptor) |
| Amino acids | 30 (with DAC modification) | 5 (pentapeptide) |
| Molecular weight | ~3,367 Da (with DAC) | ~711 Da |
| DAC variant available | Yes — extends half-life via albumin binding | N/A |
| Half-life (research models) | ~6-8 days (with DAC) | ~2 hours |
| Selectivity | GHRH receptor specific | Highly selective for GHSR-1a vs other ghrelin effects |
CJC-1295 — Mechanism and Variants
CJC-1295 is a synthetic 30-amino acid analog of growth hormone releasing hormone (GHRH). It binds to the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and pulsatile release. Two forms exist:
- CJC-1295 with DAC (Drug Affinity Complex): includes a maleimidopropionic acid linker that covalently binds albumin in vivo, extending half-life to 6-8 days. Used for sustained GHRH receptor stimulation studies.
- CJC-1295 without DAC (Mod GRF 1-29): lacks the albumin linker. Half-life ~30 minutes. Produces sharper pulsatile GH release patterns more similar to endogenous GHRH physiology.
The choice between variants depends on research design: sustained receptor occupancy (DAC) vs. physiological pulsatility (no DAC).
Ipamorelin — Mechanism
Ipamorelin is a small synthetic pentapeptide (5 amino acids) that mimics ghrelin’s action at GHSR-1a (Growth Hormone Secretagogue Receptor 1a) in the pituitary. Unlike non-selective GHSR agonists, Ipamorelin is notable for selective GH release (minimal cortisol, prolactin, or ACTH effects in research models), no appetite stimulation (unlike ghrelin itself, Ipamorelin lacks the orexigenic component in most models), and short half-life (~2 hours, producing sharp GH pulses).
The selectivity profile makes Ipamorelin a research tool for studying GHSR-1a-specific signaling separated from ghrelin’s other endocrine effects.
Why Combine CJC-1295 + Ipamorelin?
Endogenous GH release is regulated by two parallel signals: GHRH (drives synthesis and pulsatility) and ghrelin (amplifies pulse amplitude). Combining a GHRH analog with a GHRP exploits this parallel pathway architecture. In research models: the combination produces a larger GH pulse than either compound alone; the pulse shape is closer to physiological endogenous patterns; tachyphylaxis is reduced compared to single-pathway stimulation. This is why the CJC-1295 + Ipamorelin combination is one of the most-studied GH secretagogue research stacks.
Frequently Asked Questions
What’s the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analog (binds GHRH receptor); Ipamorelin is a GHRP (binds GHSR-1a / ghrelin receptor). They activate the GH secretagogue system through parallel, complementary pathways.
Should I use CJC-1295 with or without DAC?
For sustained receptor occupancy research, use CJC-1295 with DAC (~7 day half-life). For physiological pulsatility studies, use CJC-1295 without DAC (~30 minute half-life).
Why combine CJC-1295 and Ipamorelin?
The combination exploits the parallel-pathway architecture of endogenous GH regulation. The two compounds amplify GH pulse amplitude beyond what either produces alone, while reducing the tachyphylaxis that single-pathway stimulation can cause.
Does Ipamorelin cause cortisol release?
Ipamorelin is notable for selective GH release with minimal cortisol, prolactin, or ACTH effects in research models — different from less-selective GHRPs.
For research purposes only. Not for human use.